Therapeutic Apheresis in Glomerular Diseases after Kidney Transplantation
Abstract
Therapeutic apheresis is an extracorporeal treatment that selectively separates abnormal cells or substances from the blood that are linked with or cause certain disease states. It is widely used in transplantation medicine as an adjunctive therapeutic option. In kidney transplantation (KT), recurrent and de novo glomerular diseases represent the third most common cause of graft failure beyond the first year after transplantation, as current therapeutic options are limited. Evidence to support the use of therapeutic apheresis in these conditions is scarce, as it is only supported by observational studies. The purpose of this review was to examine and clarify the potential role of therapeutic apheresis and describe current evidence in the treatment of recurrent and de novo glomerular diseases after KT.
Keywords
How to Cite
References
Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med. 2002;347(2):103–9. http://dx.doi.org/10.1056/NEJMoa013036
Hariharan S, Adams MB, Brennan DC, Davis CL, First MR, Johnson CP, et al. Recurrent and de novo glomerular disease after renal transplantation: A report from Renal Allograft Disease Registry (RADR). Transplantation. 1999;68(5):635–41. http://dx.doi.org/10.1097/00007890-199909150-00007
Artero M, Biava C, Amend W, Tomlanovich S, Vincenti F. Recurrent focal glomerulosclerosis: Natural history and response to therapy. Am J Med. 1992;92(4):375. http://dx.doi.org/10.1016/0002-9343(92)90267-F
Stephanian E, Matas AJ, Mauer SM, Chavers B, Nevins T, Kashtan C, et al. Recurrence of disease in patients retransplanted for focal segmental glomerulosclerosis. Transplantation. 1992;53(4):755–7. http://dx.doi.org/10.1097/00007890-199204000-00009
Canaud G, Delville M, Legendre C. Recurrence of focal and segmental glomerulosclerosis after transplantation. Transplantation. 2016;100(2):284–7. http://dx.doi.org/10.1097/TP.0000000000000902
Delville M, Sigdel TK, Wei C, Li J, Hsieh SC, Fornoni A, et al. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med. 2014;6(256):256ra136. http://dx.doi.org/10.1126/scitranslmed.3008538
Dall’Amico R, Ghiggeri G, Carraro M, Artero M, Ghio L, Zamorani E, et al. Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children. Am J Kidney Dis. 1999;34(6):1048–55. http://dx.doi.org/10.1016/S0272-6386(99)70010-7
Cheong HI, Han HW, Park HW, Ha IS, Han KS, Lee HS, et al. Early recurrent nephritic syndrome after renal transplantation in children with focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2000;15(1):78–81. http://dx.doi.org/10.1093/ndt/15.1.78
Artero ML, Sharma R, Savin VJ, Vincenti F. Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis. 1994;23(4):574–81. http://dx.doi.org/10.1016/S0272-6386(12)80381-7
Matalon A, Markowitz GS, Joseph RE, Cohen DJ, Saal SD, Kaplan B, et al. Plasmapheresis treatment of recurrent FSGS in adult renal transplant recipients. Clin Nephrol. 2001;56(4):271–8.
Dantal J, Bigot E, Bogers W, Testa A, Kriaa F, Jacques Y, et al. Effect of plasma protein adsorption on protein excretion in kidney- transplant recipients with recurrent nephrotic syndrome. N Engl J Med. 1994;330(1):7–14. http://dx.doi.org/10.1056/NEJM199401063300102
Ponticelli C. Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation. Nephrol Dial Transplant. 2010;25(1):25–31. http://dx.doi.org/10.1093/ndt/gfp538
Kashgary A, Sontrop JM, Li L, Al-Jaishi AA, Habibullah ZN, Alsolaimani R, et al. The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: A systematic review and meta-analysis of 77 case-reports and case- series. BMC Nephrol. 2016;17(1):104. http://dx.doi.org/10.1186/s12882-016-0322-7
Vlachopanos G, Georgalis A, Gakiopoulou H. Plasma exchange for the recurrence of primary focal segmental glomerulosclerosis in adult renal transplant recipients: A meta-analysis. J Transplant. 2015;2015:639628. http://dx.doi.org/10.1155/2015/639628
Rudnicki M. FSGS recurrence in adults after renal transplantation. Biomed Res Int. 2016;2016:3295618. http://dx.doi.org/10.1155/2016/3295618
Canaud G, Zuber J, Sberro R, Royale V, Anglicheau D, Snanoudj R, et al. Intensive and prolonged treatment of focal and segmental glomerulosclerosis recurrence in adult kidney transplant recipients: A pilot study. Am J Transplant. 2009;9(5):1081–6. http://dx.doi.org/10.1111/j.1600-6143.2009.02580.x
Cravedi P, Kopp JB, Remuzzi G. Recent progress in the pathophysiology and treatment of FSGS recurrence. Am J Transplant. 2013;13(2):266–74. http://dx.doi.org/10.1111/ajt.12045
Araya CE, Dharnidharka VR. The factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis: A systematic review. J Transplant. 2011;2011:374213. http://dx.doi.org/10.1155/2011/374213
Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3:85ra46. http://dx.doi.org/10.1126/scitranslmed.3002231
Reiser J, Fornoni A. Rituximab: A boot to protect the foot. J Am Soc Nephrol. 2014;25(4):647–8. http://dx.doi.org/10.1681/ASN.2013121331
Tsagalis G, Psimenou E, Nakopoulou L, Laggouranis A. Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation. Artif Organs. 2011;35(4):420–5. http://dx.doi.org/10.1111/j.1525-1594.2010.01068.x
Hristea D, Hadaya K, Marangon N, Buhler L, Villard J, Morel P, et al. Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int. 2007;20(1):102–5. http://dx.doi.org/10.1111/j.1432-2277.2006.00395.x
Puisset F, White-Koning M, Kamar N, Huart A, Haberer F, Blasco H, et al. Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. Br J Clin Pharmacol. 2013;76(5):734–40. http://dx.doi.org/10.1111/bcp.12098
Martin-Moreno PL, Rifon J, Errasti P. Efficacy of the combination of immunoadsorption and rituximab for treatment in a case of severe focal and segmental glomerulosclerosis recurrence after renal transplantation. Blood Purif. 2018;46(2):90–3. http://dx.doi.org/10.1159/000488638
Kronbichler A, Gauckler P, Lee KH, Shin JI, Malvezzi P, Mayer G. Immunoadsorption in nephrotic syndrome: Where are we now and where are we going from here? Atheroscler Suppl. 2019;40:55–60. http://dx.doi.org/10.1016/j.atherosclerosissup.2019.08.027
Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676–87. http://dx.doi.org/10.1056/NEJMra0902814
Bresin E, Daina E, Noris M, Castelletti F, Stefanov R, Hill P, et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: Prognostic significance of genetic background. Clin J Am Soc Nephrol. 2006;1(1):88–99. http://dx.doi.org/10.2215/CJN.00050505
Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18(8):2392–400. http://dx.doi.org/10.1681/ASN.2006080811
Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013;13(3):663–75. http://dx.doi.org/10.1111/ajt.12077
Nester C, Stewart Z, Myers D, Jetton J, Nair R, Reed A, et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2011;6(6):1488–94. http://dx.doi.org/10.2215/CJN.10181110
Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome [published correction appears in Lancet. 2017 Aug 12;390(10095):648]. Lancet. 2017;390(10095):681–96. http://dx.doi.org/10.1016/S0140-6736(17)30062-4
Bambauer R, Latza R, Schiel R. Therapeutic apheresis in the treatment of hemolytic uremic syndrome in view of pathophysiological aspects. Ther Apher Dial. 2011;15(1):10–19. http://dx.doi.org/10.1111/j.1744-9987.2010.00903.x
Wijnsma KL, Ter Heine R, Moes DJAR, Langemeijer S, Schols SEM, Volokhina EB, et al. Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab. Clin Pharmacokinet. 2019;58(7):859–74. http://dx.doi.org/10.1007/s40262-019-00742-8
Garg N, Rennke HG, Pavlakis M, Zandi-Nejad K. De novo thrombotic microangiopathy after kidney transplantation. Transplant Rev (Orlando). 2018;32(1):58–68. http://dx.doi.org/10.1016/j.trre.2017.10.001
Karthikeyan V, Parasuraman R, Shah V, Vera E, Venkat KK. Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation. Am J Transplant. 2003;3(10):1289–94. http://dx.doi.org/10.1046/j.1600-6143.2003.00222.x
Epperla N, Hemauer K, Hamadani M, Friedman KD, Kreuziger LB. Impact of treatment and outcomes for patients with post-transplant drug-associated thrombotic microangiopathy. Transfusion. 2017;57(11):2775–81. http://dx.doi.org/10.1111/trf.14263
Java A, Edwards A, Rossi A, Pandey R, Gaut J, Delos Santos R, et al. Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: Case report and review of the literature. Transpl Int. 2015;28(9):1121–5. http://dx.doi.org/10.1111/tri.12582
Satoskar AA, Pelletier R, Adams P, Nadasdy GM, Brodsky S, Pesavento T, et al. De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection. Am J Transplant. 2010;10(8):1804–11. http://dx.doi.org/10.1111/j.1600-6143.2010.03178.x
Schena FP, Esposito P, Rossini M. A narrative review on C3 glomerulopathy: A rare renal disease. Int J Mol Sci. 2020;21(2): E525. http://dx.doi.org/10.3390/ijms21020525
Salvadori M, Bertoni E. Complement related kidney dis-eases: Recurrence after transplantation. World J Transplant. 2016;6(4):632–45. http://dx.doi.org/10.5500/wjt.v6.i4.632
Braun MC, Stablein DM, Hamiwka LA, Bell L, Bartosh SM, Strife CF. Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: The North American Pediatric Renal Transplant Cooperative Study experience. J Am Soc Nephrol. 2005;16(7):2225–33. http://dx.doi.org/10.1681/ASN.2005020175
Zand L, Lorenz EC, Cosio FG, Fervenza FC, Nasr Samih H, Gandhi MJ, et al. Clinical findings, pathology, and outcomes of C3GN after kidney transplantation. J Am Soc Nephrol. 2014;25(5):1110–17. http://dx.doi.org/10.1681/ASN.2013070715
Alasfar S, Carter-Monroe N, Rosenberg AZ, Montgomery RA, Alachkar N. Membranoproliferative glomerulonephritis recurrence after kidney transplantation: Using the new classification. BMC Nephrol. 2016;17:7. http://dx.doi.org/10.1186/s12882-015-0219-x
Kurtz KA, Schlueter AJ. Management of membranoproliferative glomerulonephritis type II with plasmapheresis. J Clin Apher. 2002;17(3):135–7. http://dx.doi.org/10.1002/jca.10026
McCaughan JA, O’Rourke DM, Courtney AE. Recurrent dense deposit disease after renal transplantation: An emerging role for complementary therapies. Am J Transplant. 2012;12(4):1046–51. http://dx.doi.org/10.1111/j.1600-6143.2011.03923.x
Kumar A, Bharati J, Nada R, Singh S, Sharma A, Gupta KL, et al. Utility of plasma exchange in early recurrent C3 glomerulopathy. Indian J Transplant. 2019;13:122–6. http://dx.doi.org/10.4103/ijot.ijot_78_18
Vivarelli M, Emma F. Treatment of C3 glomerulopathy with complement blockers. Semin Thromb Hemost. 2014;40(4):472–7. http://dx.doi.org/10.1055/s-0034-1375299
Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol. 2012;7(5):748–56. http://dx.doi.org/10.2215/CJN.12901211
Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, et al. Randomized trial of C5a receptor inhibitor Avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017;28(9):2756–67. http://dx.doi.org/10.1681/ASN.2016111179
Sciascia S, Cuadrado MJ, Khamashta M, Roccatello D. Renal involvement in antiphospholipid syndrome. Nat Rev Nephrol. 2014;10(5):279–89. http://dx.doi.org/10.1038/nrneph.2014.38
Barbour TD, Crosthwaite A, Chow K, Finlay MJ, Better N, Hughes PD, et al. Antiphospholipid syndrome in renal transplantation. Nephrology (Carlton). 2014;19(4):177–85. http://dx.doi.org/10.1111/nep.12217
Phillips AO, Jones HW, Hambley H, Hillis AN, Hendry BM. Prevalence of lupus anticoagulant and anticardiolipin antibodies in haemodialysis patients. Nephron. 1993;65(3):350–3. http://dx.doi.org/10.1159/000187511
Ducloux D, Pellet E, Fournier V, Rebibou JM, Bresson-Vautrin C, Racadot E, et al. Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients. Transplantation. 1999;67(1):90–3. http://dx.doi.org/10.1097/00007890-199901150-00015
Vaidya S, Sellers R, Kimball P, Shanahan T, Gitomer J, Gugliuzza K, et al. Frequency, potential risk and therapeutic intervention in end-stage renal disease patients with antiphospholipid antibody syndrome: A multicenter study. Transplantation. 2000;69(7):1348–52. http://dx.doi.org/10.1097/00007890-200004150-00023
Forman JP, Lin J, Pascual M, Denton MD, Tolkoff-Rubin N. Significance of anticardiolipin antibodies on short and long term allograft survival and function following kidney transplantation. Am J Transplant. 2004;4(11):1786–91. http://dx.doi.org/10.1046/j.1600-6143.2004.00602.x
Vaidya S, Gugliuzza K, Daller JA. Efficacy of anticoagulation therapy in end-stage renal disease patients with antiphospholipid antibody syndrome. Transplantation. 2004;77(7):1046–9. http://dx.doi.org/10.1097/01.TP.0000119157.81765.46
Ruffatti A, Marson P, Valente M, Ciprian M, Tonello M, Marchini F, et al. Plasma exchange in a patient with primary antiphospholipid syndrome undergoing kidney transplantation. Transpl Int. 2007;20(5):475–7. http://dx.doi.org/10.1111/j.1432-2277.2007.00454.x
Sofue T, Hayashida Y, Hara T, Kawakami K, Ueda N, Kushida Y, et al. Plasmapheresis in a patient with antiphospholipid syndrome before living-donor kidney transplantation: A case report. BMC Nephrol. 2014;15:167. http://dx.doi.org/10.1186/1471-2369-15-167
Asherson RA, Cervera R, de Groot PG, Erkan D, Boffa MC, Piette JC, et al. Catastrophic Antiphospholipid Syndrome Registry Project Group. Catastrophic antiphospholipid syndrome: International consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12(7):530–4. http://dx.doi.org/10.1191/0961203303lu394oa
Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med. 2010;362(18):1744–5. http://dx.doi.org/10.1056/NEJMc0910965
Kotanko P, Pusey CD, Levy JB. Recurrent glomerulonephritis following renal transplantation. Transplantation. 1997;63(8):1045–52. http://dx.doi.org/10.1097/00007890-199704270-00001
McAdoo SP, Pusey CD. Anti-glomerular basement membrane disease. Clin J Am Soc Nephrol. 2017;12(7):1162–72. http://dx.doi.org/10.2215/CJN.01380217
Göbel J, Olbricht CJ, Offner G, Helmchen U, Repp H, Koch KM, et al. Kidney transplantation in Alport’s syndrome: Long-term outcome and allograft anti-GBM nephritis. Clin Nephrol. 1992;38(6):299–304.
Kalluri R, Weber M, Netzer KO, Sun MJ, Neilson EG, Hudson BG. COL4A5 gene deletion and production of post-transplant anti-alpha 3(IV) collagen alloantibodies in Alport syndrome. Kidney Int. 1994;45(3):721–6. http://dx.doi.org/10.1038/ki.1994.96
Mallett A, Tang W, Clayton PA, Stevenson S, McDonald SP, Hawley CM, et al. End-stage kidney disease due to Alport syn-drome: Outcomes in 296 consecutive Australia and New Zealand Dialysis and Transplant Registry cases. Nephrol Dial Transplant. 2014;29(12):2277–86. http://dx.doi.org/10.1093/ndt/gfu254
Biesenbach P, Kain R, Derfler K, Perkmann T, Soleiman A, Benharkou A, et al. Long-term outcome of anti-glomerular basement membrane antibody disease treated with immunoadsorption. PLoS One. 2014;9(7):e103568. http://dx.doi.org/10.1371/journal.pone.0103568
Zhang YY, Tang Z, Chen DM, Gong DH, Ji DX, Liu ZH. Comparison of double filtration plasmapheresis with immunoadsorption therapy in patients with anti-glomerular basement membrane nephritis. BMC Nephrol. 2014;15:128. http://dx.doi.org/10.1186/1471-2369-15-128
Soveri I, Mölne J, Uhlin F, Nilsson T, Kjellman C, Sonesson E, et al. The IgG-degrading enzyme of Streptococcus pyogenes causes rapid clearance of anti-glomerular basement membrane antibodies in patients with refractory anti-glomerular basement membrane disease. Kidney Int. 2019;96(5):1234–8. http://dx.doi.org/10.1016/j.kint.2019.06.019
Moran S, Little MA. Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis. Curr Opin Rheumatol. 2014;26(1):37–41. http://dx.doi.org/10.1097/BOR.0000000000000006
Geetha D, Kant S. Renal transplantation in anti-neutrophil cytoplasmic antibody vasculitis. Expert Rev Clin Immunol. 2018;14(3):235–40. http://dx.doi.org/10.1080/1744666X.2018.1440205
Walters G. Role of therapeutic plasmapheresis in ANCA-associated vasculitis. Pediatr Nephrol. 2016;31(2):217–25. http://dx.doi.org/10.1007/s00467-014-3038-6
Apaydin S. The treatment of ANCA-associated rapidly-progressive glomerulonephritis and Goodpasture syndrome with therapeutic apheresis. Transfus Apher Sci. 2018;57(1):8–12. http://dx.doi.org/10.1016/j.transci.2018.02.007
Walsh M, Merkel PA, Peh CA, Szpirt WM, Puèchal X, Fujimoto S, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382(7):622–31. http://dx.doi.org/10.1056/NEJMoa1803537
Merkel PA, Jayne DR, Wang C, Hillson J, Bekker P. Evaluation of the safety and efficacy of Avacopan, a C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-as-sociated vasculitis treated concomitantly with rituximab or cyclophosphamide/azathioprine: Protocol for a randomized, double-blind, active-controlled, phase 3 trial. JMIR Res Protoc. 2020;9(4):e16664. http://dx.doi.org/10.2196/16664
Copyright and licence
Copyright (c) 2020 Maurizio Salvadori, Aris Tsalouchos
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
